. 2020 Apr 10;15(4):e0231427. doi: 10.1371/journal.pone.0231427

Table 3. Cumulative survival rates of patients with unresectable hepatocellular carcinoma (HCC) receiving lenvatinib and factors associated with patient outcome.

		Kaplan Meier method				Cox proportional hazard regression analysis
		Cumulative Survival rates (%)			P values	Hazard ratio	95% Confidence Interval	P values
		Total	24 weeks	48 weeks
Total		69	88.5	73.9	−
Age: years	< 70	23	84.6	76.2	0.79
Age: years	≥ 70	46	90.2	72.7	0.79
Etiology	HCV	37	91.5	68.2	0.99
Etiology	Others	32	84.5	84.5	0.99
Child-Pugh score	5	31	100	86.9	0.01	−	−	−
Child-Pugh score	6, 7	38	78.6	63.1	0.01	−	−	−
mALBI grade	1, 2a	40	100	90.9	<0.01	0.16	0.04–0.59	0.006
mALBI grade	2b	29	72.6	46.6	<0.01	1	0.04–0.59	0.006
BCLC stages	A	17	100	71.4	0.09
	B	22	95.0	76.7
	C	30	76.3	70.4
Vp	0	50	93.3	76.8	0.41
Vp	1–3	19	74.2	64.9	0.41
Extrahepatic metastasis	Absent	56	89.9	71.3	0.37
Extrahepatic metastasis	Present	13	81.8	81.8	0.37
AFP: ng/mL	< 200	48	93.2	74.0	0.10
AFP: ng/mL	≥ 200	21	73.9	73.9	0.10
TACE, TAI	Naïve	7	83.3	83.3	0.94
	Experienced	62	89.1	73.3	0.94
	TACE refractoriness	21	90.5	70.4
Molecular targeted agents	Naïve	55	89.4	73.3	0.72
Molecular targeted agents	Experienced	14	84.6	74.0	0.72
Early efficacy	CR, PR	26	95.5	95.5	<0.01	0.14	0.02–1.10	0.062
Early efficacy	no response	43	84.0	54.3	<0.01	1	0.02–1.10	0.062

mALBI: modified albumin bilirubin, BCLC: Barcelona Clinic Liver Cancer, Vp; tumor thrombosis in the portal vein, AFP: alpha-fetoprotein, TACE: transcatheter arterial chemoembolization, TAI: transcatheter arterial infusion chemotherapy, CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease.